Importantly, since ion channels are also involved at all stages of the overall cancer process, their blockers may offer unique multi-faceted advantages for T-cell based immunotherapies, including combinations with PD-1 blockade (196, 198, 200) (Figure 8). The gene discussed is PDCD1; the disease is cancer.